Tryptophan-degrading enzymes in tumoral immune resistance

Frontiers in Immunology

Volumn 6, Issue FEB, 2015, Pages

  van Baren, Nicolas ^a,b,c   Van den Eynde, Benoît J ^a,b,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b Walloon Excellence in Life Sciences and Biotechnology (WELBIO)   (Belgium)

^c DE DUVE INSTITUTE   (Belgium)

Author keywords

Adaptive resistance; Dendritic cells; Immunosuppression; Indoleamine 2,3 dioxygenase; Tryptophan; Tryptophan 2,3 dioxygenase; Tumor

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CD123 ANTIGEN; CD163 ANTIGEN; CD83 ANTIGEN; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE 2; INTERLEUKIN 1BETA; INTERLEUKIN 6; KYNURENINE; LANGERIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PROSTAGLANDIN E2; SUPPRESSOR OF CYTOKINE SIGNALING 3; T6 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER IMMUNOTHERAPY; CELL CYCLE ARREST; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME STRUCTURE; GENETIC POLYMORPHISM; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TOXOPLASMOSIS; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR RESISTANCE;

EID: 84926652188     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00034     Document Type: Review

References (74)

1. Kudo Y, Boyd CA. Characterisation of l-tryptophan transporters in human placenta: a comparison of brush border and basal membrane vesicles. J Physiol (2001) 531:405-16. doi: 10.1111/j.1469-7793.2001.0405i.x
2. Seymour RL, Ganapathy V, Mellor AL, Munn DH. A high-affinity, tryptophan-selective amino acid transport system in human macrophages. J Leukoc Biol (2006) 80:1320-7. doi:10.1189/jlb.1205727
3. Silk JD, Lakhal S, Laynes R, Vallius L, Karydis I, Marcea C, et al. IDO induces expression of a novel tryptophan transporter in mouse and human tumor cells. J Immunol (2011) 187:1617-25. doi:10.4049/jimmunol.1000815
4. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med (1999) 189:1363-72. doi:10.1084/jem.189.9.1363
5. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase. Immunity (2005) 22:633-42. doi:10.1016/j.immuni.2005.03.013
6. Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by d-l-methyl-tryptophan. Oncoimmunology (2012) 1:1460-8. doi:10.4161/onci.21716
7. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ (2002) 9:1069-77. doi:10.1038/sj.cdd.4401073
8. Terness P, Bauer TM, Röse L, Dufter C, Watzlik A, Simon H, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2, 3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med (2002) 196:447-57. doi:10.1084/jem.20020052
9. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol (2006) 176:6752-61. doi:10.4049/jimmunol.176.11.6752
10. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol (2010) 185:3190-8. doi:10.4049/jimmunol.0903670
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013
12. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med (2003) 9:1269-74. doi:10.1038/nm934
13. Koblish HK, Hansbury MJ, Bowman KJ, Yang G, Neilan CL, Haley PJ, et al. Hydroxyamidine inhibitors of indoleamine-2, 3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther (2010) 9:489-98. doi:10.1158/1535-7163.MCT-09-0628
14. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med (2005) 11:312-9. doi:10.1038/nm1196
15. Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frederick R, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2, 3-dioxygenase. Proc Natl Acad Sci U S A (2012) 109:2497-502. doi:10.1073/pnas.1113873109
16. Ball HJ, Sanchez-Perez A, Weiser S, Austin CJ, Astelbauer F, Miu J, et al. Characterization of an indoleamine 2, 3-dioxygenase-like protein found in humans and mice. Gene (2007) 396:203-13. doi:10.1016/j.gene.2007.04.010
17. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2, 3-dioxygenase inhibitory compound d-l-methyl-tryptophan. Cancer Res (2007) 67:7082-7. doi:10.1158/0008-5472.CAN-07-1872
18. Batabyal D, Yeh SR. Human tryptophan dioxygenase: a comparison to indoleamine 2, 3-dioxygenase. J Am Chem Soc (2007) 129:15690-701. doi:10.1021/ja076186k
19. Knox WE. Two mechanisms which increase in vivo the liver tryptophan peroxidase activity: specific enzyme adaptation and stimulation of the pituitary adrenal system. Br J Exp Pathol (1951) 32:462-9.
20. Kanai M, Funakoshi H, Takahashi H, Hayakawa T, Mizuno S, Matsumoto K, et al. Tryptophan 2, 3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol Brain (2009) 2:8. doi:10.1186/1756-6606-2-8
21. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The genotype-tissue expression (GTEx) project. Nat Genet (2013) 45:580-5. doi:10.1038/ng.2653
22. Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 45:1113-20. doi:10.1038/ng.2764
23. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol (2010) 11:R106. doi:10.1186/gb-2010-11-10-r106
24. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature (2011) 478:197-203. doi:10.1038/nature10491
25. Salter M, Hazelwood R, Pogson CI, Iyer R, Madge DJ. The effects of a novel and selective inhibitor of tryptophan 2, 3-dioxygenase on tryptophan and serotonin metabolism in the rat. Biochem Pharmacol (1995) 49:1435-42. doi:10.1016/0006-2952(95)00006-L
26. Dolusic E, Larrieu P, Moineaux L, Stroobant V, Pilotte L, Colau D, et al. Tryptophan 2, 3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer Immunomodulators. J Med Chem (2011) 54:5320-34. doi:10.1021/jm2006782
27. Alex Bishop G, Bertolino PD, Bowen DG, McCaughan GW. Tolerance in liver transplantation. Best Pract Res Clin Gastroenterol (2012) 26:73-84. doi:10.1016/j.bpg.2012.01.003
28. Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature (2014) 511:184-90. doi:10.1038/nature13323
29. Rafice SA, Chauhan N, Efimov I, Basran J, Raven EL. Oxidation of l-tryptophan in biology: a comparison between tryptophan 2, 3-dioxygenase and indoleamine 2, 3-dioxygenase. Biochem Soc Trans (2009) 37:408-12. doi:10.1042/BST0370408
30. Pantouris G, Serys M, Yuasa HJ, Ball HJ, Mowat CG. Human indoleamine 2, 3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2, 3-dioxygenase-1. Amino Acids (2014) 46:2155-63. doi:10.1007/s00726-014-1766-3
31. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science (1998) 281:1191-3. doi:10.1126/science.281.5380.1191
32. Mellor AL, Baban B, Chandler P, Marshall B, Jhaver K, Hansen A, et al. Cutting edge: induced indoleamine 2, 3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol (2003) 171:1652-5. doi:10.4049/jimmunol.171.4.1652
33. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol (2002) 3:1097-101. doi:10.1038/ni846
34. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer (2014) 2:3. doi:10.1186/2051-1426-2-3
35. Baban B, Chandler P, McCool D, Marshall B, Munn DH, Mellor AL. Indoleamine 2, 3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol (2004) 61:67-77. doi:10.1016/j.jri.2003.11.003
36. de Faudeur G, de Trez C, Muraille E, Leo O. Normal development and function of dendritic cells in mice lacking IDO-1 expression. Immunol Lett (2008) 118:21-9. doi:10.1016/j.imlet.2008.02.006
37. Chang MY, Smith C, DuHadaway JB, Pyle JR, Boulden J, Soler AP, et al. Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2, 3-dioxygenase. Cancer Biol Ther (2011) 12:1050-8. doi:10.4161/cbt.12.12.18142
38. Theate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, et al. Extensive profiling of the expression of the indoleamine 2, 3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res (2014): doi:10.1158/2326-6066.CIR-14-0137
39. Dai X, Zhu BT. Indoleamine 2, 3-dioxygenase tissue distribution and cellular localization in mice: implications for its biological functions. J Histochem Cytochem (2010) 58:17-28. doi:10.1369/jhc.2009.953604
40. Blaschitz A, Gauster M, Fuchs D, Lang I, Maschke P, Ulrich D, et al. Vascular endothelial expression of indoleamine 2, 3-dioxygenase 1 forms a positive gradient towards the feto-maternal interface. PLoS One (2011) 6:e21774. doi:10.1371/journal.pone.0021774
41. Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov (2012) 2:722-35. doi:10.1158/2159-8290.CD-12-0014
42. Wang Y, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M, et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med (2010) 16:279-85. doi:10.1038/nm.2092
43. Sedlmayr P, Blaschitz A, Wintersteiger R, Semlitsch M, Hammer A, MacKenzie CR, et al. Localization of indoleamine 2, 3-dioxygenase in human female reproductive organs and the placenta. Mol Hum Reprod (2002) 8:385-91. doi:10.1093/molehr/8.4.385
44. Berger TG, Feuerstein B, Strasser E, Hirsch U, Schreiner D, Schuler G, et al. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods (2002) 268:131-40. doi:10.1016/S0022-1759(02)00189-8
45. Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2, 3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood (2005) 106:2375-81. doi:10.1182/blood-2005-03-0979
46. Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, Bianchi R, et al. SOCS3 drives proteasomal degradation of indoleamine 2, 3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci U S A (2008) 105:20828-33. doi:10.1073/pnas.0810278105
47. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, et al. Indoleamine 2, 3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol (2011) 12:870-8. doi:10.1038/ni.2077
48. Trabanelli S, Ocadlikova D, Ciciarello M, Salvestrini V, Lecciso M, Jandus C, et al. The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. J Immunol (2014) 192:1231-40. doi:10.4049/jimmunol.1300720
49. Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R. Indoleamine 2, 3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res (2011) 17:6985-91. doi:10.1158/1078-0432.CCR-11-1331
50. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 515:563-7. doi:10.1038/nature14011
51. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 515:568-71. doi:10.1038/nature13954
52. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 4:127ra37. doi:10.1126/scitranslmed.3003689
53. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5:200ra116. doi:10.1126/scitranslmed.3006504
54. Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J (2010) 16:399-403. doi:10.1097/PPO.0b013e3181eacbd8
55. Litzenburger UM, Opitz CA, Sahm F, Rauschenbach KJ, Trump S, Winter M, et al. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget (2014) 5:1038-51.
56. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 210:1389-402. doi:10.1084/jem.20130066
57. Riesenberg R, Weiler C, Spring O, Eder M, Buchner A, Popp T, et al. Expression of indoleamine 2, 3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res (2007) 13:6993-7002. doi:10.1158/1078-0432.CCR-07-0942
58. Bromwich EJ, McArdle PA, Canna K, McMillan DC, McNicol AM, Brown M, et al. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer (2003) 89:1906-8. doi:10.1038/sj.bjc.6601400
59. Brody JR, Costantino CL, Berger AC, Sato T, Lisanti MP, Yeo CJ, et al. Expression of indoleamine 2, 3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle (2009) 8:1930-4. doi:10.4161/cc.8.12.8745
60. Lee JR, Dalton RR, Messina JL, Sharma MD, Smith DM, Burgess RE, et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest (2003) 83:1457-66. doi:10.1097/01.LAB.0000090158.68852.D1
61. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2, 3-dioxygenase. Science (2002) 297:1867-70. doi:10.1126/science.1073514
62. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, et al. Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest (2004) 114:280-90. doi:10.1172/JCI21583E1
63. Yuasa HJ, Ball HJ, Ho YF, Austin CJ, Whittington CM, Belov K, et al. Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials. Comp Biochem Physiol B Biochem Mol Biol (2009) 153:137-44. doi:10.1016/j.cbpb.2009.02.002
64. Fatokun AA, Hunt NH, Ball HJ. Indoleamine 2, 3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease. Amino Acids (2013) 45:1319-29. doi:10.1007/s00726-013-1602-1
65. Fukunaga M, Yamamoto Y, Kawasoe M, Arioka Y, Murakami Y, Hoshi M, et al. Studies on tissue and cellular distribution of indoleamine 2, 3-dioxygenase 2: the absence of IDO1 upregulates IDO2 expression in the epididymis. J Histochem Cytochem (2012) 60:854-60. doi:10.1369/0022155412458926
66. Croitoru-Lamoury J, Lamoury FM, Caristo M, Suzuki K, Walker D, Takikawa O, et al. Interferon-gamma regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2, 3 dioxygenase (IDO). PLoS One (2011) 6:e14698. doi:10.1371/journal.pone.0014698
67. Divanovic S, Sawtell NM, Trompette A, Warning JI, Dias A, Cooper AM, et al. Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J Infect Dis (2012) 205:152-61. doi:10.1093/infdis/jir621
68. Sun T, Chen XH, Tang ZD, Cai J, Wang XY, Wang SC, et al. Novel 1-alkyl-tryptophan derivatives downregulate IDO1 and IDO2 mRNA expression induced by interferon-gamma in dendritic cells. Mol Cell Biochem (2010) 342:29-34. doi:10.1007/s11010-010-0465-y
69. Metz R, Smith C, DuHadaway JB, Chandler P, Baban B, Merlo LM, et al. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. Int Immunol (2014) 26:357-67. doi:10.1093/intimm/dxt073
70. Merlo LM, Pigott E, DuHadaway JB, Grabler S, Metz R, Prendergast GC, et al. IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis. J Immunol (2014) 192:2082-90. doi:10.4049/jimmunol.1303012
71. Lob S, Konigsrainer A, Schafer R, Rammensee HG, Opelz G, Terness P. Levo-but not dextro-l-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood (2008) 111:2152-4. doi:10.1182/blood-2007-10-116111
72. Lob S, Konigsrainer A, Zieker D, Brucher BL, Rammensee HG, Opelz G, et al. IDO1 and IDO2 are expressed in human tumors: levo-but not dextro-l-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother (2008) 58:153-7. doi:10.1007/s00262-008-0513-6
73. Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, et al. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg (2009) 208:781-7. doi:10.1016/j.jamcollsurg.2008.12.018
74. Eldredge HB, Denittis A, Duhadaway JB, Chernick M, Metz R, Prendergast GC. Concurrent whole brain radiotherapy and short-course chloroquine in patients with brain metastases: a pilot trial. J Radiat Oncol (2013) 2:315-21. doi:10.1007/s13566-013-0111-x